Abstract Library

#3007 An mRNA-based Classifier Identifies PanNETs with Different Clinicopathological Characteristics

Introduction: Pancreatic neuroendocrine tumors (PanNETs) are a heterogeneous group of neoplasms that varies from indolent to highly aggressive diseases. Previous studies have suggested alterations of ATRX/DAXX as biomarkers of dismal prognosis, yet inconclusive data (especially in the metastatic setting) prevent those biomarkers to be used as routine clinical tests.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Vicentini C, Barbi S, Bersani S, Rusev B, Lawlor R,

Keywords: PanNET, gene expression profile, ATRX/DAXX mutations, patients’ stratification.,

#2943 Risk Stratification of Well-Differentiated Rectal Neuroendocrine Tumors

Introduction: How to screen patients with well-differentiated rectal neuroendocrine tumors (NETs) who had high risk to develop metastatic disease and poor survival was still less cleared.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Zhang Y, Chen L, Zhang Y, Guan X, Pan Y,

Keywords: rectal neuroendocrine tumors, metastasis, survival,

#2790 Trends of Incidence and Prognosis of Gastric Neuroendocrine Neoplasms - A Study Based on SEER and Our Multicenter Research

Introduction: The incidence of gastric neuroendocrine neoplasms (GNENs) is increasing but we still lack effective tools for risk stratification so far.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Hu P, Bai J, Liu M, Tang Q, Chen T,

Keywords: gastric neuroendocrine neoplasms, incidence, nomogram, overall survival,

#2216 Predicting Response to PRRT: Development and Validation of a Blood-Based Predictive Biomarker

Introduction: We have developed a blood-based tool (gene expression analysis and tumor grade) for predicting PRRT efficacy.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Bodei L

Authors: Bodei L, Kidd M, van der Zwan W, Singh A, Severi S,

Keywords: Biomarker, carcinoid, PRRT, prediction, therapy, efficacy, stratification,

#2215 Development of Multiplex Biomarker Assay to Subtype Pancreatic Neuroendocrine Tumors (PanNETs) with Distinct Prognosis and Mutations

Introduction: Overall 5-year survival for PanNETs ranges from 25-100%. The treatment paradigm for PanNETs largely based upon grades, which is significantly heterogeneous. We previously defined three molecular subtypes (distributed grades) of PanNETs using PanNETassigner signature. There is an unmet clinical need for prognostic and predictive biomarkers and clinically-relevant assays to complement grade and improve patient stratification.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Sadanandam A

Authors: Sadanandam A, Young K, Nyamundanda G, Ragulan C, Lawlor R,

Keywords: molecular subtypes, biomarker assay, clinical assay, patient prognosis, subtype-specific mutations, NanoString Technologies, low-cost assay, pancreatic neuroendocrine tumors, grades, PanNETassigner subtype, patient stratification, pnet,